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Abstract
Purpose: PFS is often used as a surrogate endpoint for OS in metastatic breast cancer studies. We have
evaluated the association of treatment effect on PFS with significant HROS (and how this association
is affected by other factors) in published prospective metastatic breast cancer studies.
Methods: A systematic literature search in PubMed identified prospective metastatic breast cancer
studies. Treatment effects on PFS were determined using hazard ratio (HRPFS), increase in median
PFS (∆MEDPFS) and % increase in median PFS (%∆MEDPFS). Diagnostic accuracy of PFS measures
(HRPFS , ∆MEDPFS and %∆MEDPFS) in predicting significant HROS was assessed using receiver
operating characteristic (ROC) curves and classification tree approach (CART).
Results: Seventy-four cases (i.e., treatment to control comparisons) from 65 individual publications
were identified for the analyses. Of these, 16 cases reported significant treatment effect on HROS at 5%
level of significance. Median number of deaths reported in these cases were 153. Area under the ROC
curve (AUC) for diagnostic measures as HRPFS , ∆MEDPFS and %∆MEDPFS were 0.69, 0.70 and
0.75, respectively. Classification tree results identified %∆MEDPFS and number of deaths as diagnostic
measure for significant HROS . Only 7.9% (3/39) cases with ∆MEDPFS shorter than 48.27% reported
significant HROS . There were 7 cases with ∆MEDPFS of 48.27% or more and number of deaths reported
as 227 or more – of these 5 cases reported significant HROS .
Conclusion: %∆MEDPFS was found to be a better diagnostic measure for predicting significant HROS .
Our analysis results also suggest that consideration of total number of deaths may further improve its
diagnostic performance. Based on our study results, the studies with 50% improvement in median PFS
are more likely to produce significant HROS if the total number of OS events at the time of analysis is
227 or more.
Keywords: Metastatic breast cancer, Progression free survival, Overall survival, surrogacy, meta-
analysis, ROC curve, classification tree, Surrogate threshold effect.
Introduction
As per national cancer institute, in the U.S., breast cancer is the second most common non-skin can-
cer and the second leading cause of cancer-related deaths in women; and, therefore, there has always
been a high demand for novel breast cancer therapies. At the time of preparing this manuscript,
based on ClinicalTrial.gov search [1], 175 phase III breast cancer studies were actively recruiting
patients. For breast cancer therapies, the main goal is to improve overall survival (OS) and quality
of life [2, 3]. US FDA guideline [4] states that “[overall] survival is considered the most reliable cancer
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endpoint”. Due to the advancement in metastatic breast cancer management and therapies, there
has been marked improvement in OS in breast cancer patients in the last few decades. Conequently,
patients need to be followed-up for longer period of time to observe sufficient number of OS events
(i.e., deaths) [5] before treatment effect on OS can be evaluated statistically. Further, as many pa-
tients switch to second line (and beyond) therapies upon progression, the OS time may be influenced
by post-progression therapy. For these reasons, surrogate endpoints such as progression-free survival
(PFS) or objective response rate (ORR) are being increasingly used for accelerated approvals, with
PFS being the one used most often [2]. The basis for using PFS as surrogate endpoint for OS is as
follows: cancer progression represents an ominous march toward death from malignancy. Hence, the
longer it takes for the cancer to progress, the longer a patient will live [6]. In general, PFS has not
been statistically validated for surrogacy of OS yet in breast cancer studies[2, 4]. Reported results
regarding association between Hazard ratio of PFS and OS in the metastatic breast cancer studies
are mixed: For example, Hackshaw et al. [7] found a correlation of 0.87; Burzykowski et al. [8]
reported correlation of 0.48; Michiels et al. [9] reported R2 (i.e. proportion of the variance in the
true endpoint that is explained by the surrogate endpoint) as 0.51.
According to Prentice’s definition[10], in order for PFS to be a “statistically validated” surrogate
endpoint for OS, “test for null hypothesis of no treatment effect in PFS” should be a valid “test for
null hypothesis of no treatment effect in OS”. The test for treatment effect on OS is carried out by
testing HROS=1, where HROS is the hazard ratio (HR) of OS. However, many randomized clinical
trials failed to demonstrate significant treatment effect in OS despite demonstrating significant treat-
ment effect in PFS. The current project attempts to investigate the trial level surrogacy in breast
cancer studies from a diagnostic testing perspective using nonparametric approaches. It is important
to note that our investigation differs from previous investigations [7, 8, 11, 12, 13, 14, 15, 16] based
on meta-analytic methods, where the primary purpose was to examine the strength of treatment
effect on PFS to predict treatment effect on OS at trial level. The definition of trial level surrogacy
in the current investigation is intuitive and aligned with the ultimate question that all stakeholders,
regulators in particular, are often seeking an answer to, from a phase III cancer clinical trial – Is
there a statistically significant OS benefit in the new treatment that is discernible from the data
on progression-free survival (PFS) in metastatic breast cancer studies? This definition of trial level
surrogacy was also cosidered by Burzykowski and Buyse [17] as it can be useful to estimate the
“Surrogate threshold effect”. Surrogate threshold effect can be defined as the minimum treatment
effect on PFS measure that is required to predict statistically significant HROS .
Our goal was to evaluate the trial level surrogacy of PFS for OS solely based on published clinical
trial results. Burzykowski et al. [8] evaluated trial level surrogacy by fitting simple (log-) linear
regression analysis to model HROS with ratio of median PFS time and then used R2 as a measure of
trial level surrogacy. Buyse et al. [18] proposed to estimate trial level surrogacy using R2 as well, but
in a more sophisticated way using trial specific random effects. These methods make various model
assumptions such as PFS and OS are linearly associated [8] or some distributional assumption [18]).
As Venook and Tabernero [6] have pointed out association of PFS with OS may be complicated in
today’s era and, therefore, a simplified linear model may not be sufficient to describe the association.
Further, the use of R2 is heavily impacted by the presence of outlier [19]. Another problem related to
R2 is the difficulty in interpreting its value [17]. For these reasons, we have adopted non-parametric
approaches to evaluate the trial level surrogacy which, unlike parametric methods, do not require
to make distributional assumptions or to pre-specify the from of the association. The advnatges
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Table 1: Summary of publications by journal and year
Journal of Publication 2014-2015 2012-2013 2010-2011 2005-2009 2000-2004 Total
Journal of Clinical Oncology 7 9 4 5 3 28
Breast Cancer Research
Treatment 3 2 4 2 11
Annals of Oncology 5 3 1 9
Cancer 1 1 1 3
Clinical Breast Cancer 3 3
Clinical Cancer Research 2 2
Others 1 4 1 2 1 9
Total 17 20 13 10 5 65
of non-parametric methods are that these methods are completley data-driven and free from model
assumptions. Consequently, non-parametric methods have obvious advantage of producing results
which are solely based on observed data and are not dependent on unverifiable model assumptions.
Non-parametric methods can be also useful (a) to find out which PFS measure is relatively more
important in predicting significant HROS , (b) to study the influence of other factors (e.g., sample
size and total number of events) on the association of PFS measure and significant HROS as, for
example, the power for statistical test of HROS is a function of total number of OS events, and
(c) to estimate surrogate threshold effect. Results from non-parametric methods are often easy to
interpret, and allow granular visualization of the results. For this project, breast cancer studies were
our focus, but the similar investigation can be carried out for other indications as well. Throughout
the article, (unless otherwise mentioned), ‘statistically significant’ would imply that the significance
was in favor of the treatment.
Methods
Literature search
A systematic literature search in PubMed (July 2015) was performed to identify published prospective
studies on metastatic breast cancer research with both PFS and OS comparison results reported.
The search syntax used was as follows: “(((Breast Cancer[Title]) AND Randomized[Title/Abstract])
AND Progression free survival[Text Word]) AND Overall survival[Text Word]”. The PubMed search
returned 181 publications between Jul-2000 and Jul-2015. Many of these studies were systematic
literature review or meta-analyses and hence dropped. Further, studies with either PFS or OS not
reported were also excluded. We were able to find 64 individual prospective studies [20, 21, 22, 23,
24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50,
51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 75, 76, 77, 78,
79, 80, 81, 82, 83, 84] where both PFS and OS comparison results were reported. In addition, in
one publication [74], instead of PFS, time to progression (TTP) was reported and that study was
included. Therefore, we had total of 65 publications for the meta-analyses.
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Data extraction
Of the 65 selected publications, in seven prospective studies [25, 26, 27, 57, 59, 61, 84], two pairs
of treatment-to-control comparisons were reported and in one prospective study [35], three pairs of
treatment-to-control comparisons were reported. Therefore, we had total of 74 treatment-to-control
comparison available for the meta-analyses. For each treatment-to-control comparison, the following
information were extracted: randomization status, blinding status (open or blinded), total sample
size (treatment plus control), total number of events (treatment plus control), median PFS, median
OS, HR (hazard ratio) in PFS (HRPFS), HR in OS HROS , reported p-value (or significance status)
for HRPFS and reported p-value (or significance status) for HROS . In case both local and central
PFS assessments were reported, the one which was reported as primary endpoint was considered.
Statistical methods
Treatment effect on PFS was determined using the following measures: hazard ratio (HRPFS),
increase in median PFS (∆MEDPFS) and % increase in median PFS (%∆MEDPFS). All three mea-
sures were used as diagnostic tools for predicting statistically significant HROS in favor of treatment
(yes/no).
We have assessed the trial level surrogacy of PFS for OS by evaluating the diagnostic accuracy of
these comparative PFS measures to predict statistically significant HROS . Diagnostic accuracy of
comparative PFS measures (HRPFS , ∆MEDPFS and %∆MEDPFS) in predicting significant HROS
was assessed using receiver-operating characteristic (ROC) curve [85], and classification tree (using
CART algorithm [87]) approach. Empirical ROC curves were drawn plotting the true positive rate
(proportion of correct prediction of significant HROS based on comparative PFS measure among
those reporting significant treatment effect on HROS) against the false positive rate (proportion of
wrong prediction of significant HROS based on PFS measure among those reported non- significant
treatment effect on HROS). True positive rate, and false positive rate were obtained at each unique
value of comparative PFS measures. For a given unique value of x, if comparative PFS measure was
greater than or equal to x, then it was predicted that HROS will be signifacant; otherwise not. The
accuracy of the diagnostic measure was assessed by numerically computing the area under ROC curve
(AUC), with larger AUC implying better accuracy. Optimal cut-off points based on ROC curve were
identified according to Youden’s index[88]. According to Youden’s criteria a optimum cut-off point
for prediction of significant HROS would be one that maximizes the difference between true positive
rate and false positive rate.
We have utilized classification tree to answer following questions: (a) which trial level measure of
treatment benefit in PFS has stronger association with significant HROS in favor of treatment –
HRPFS or (%) median improvement in PFS? (b) Is there any other factor(s) (e.g., total number
of deaths) that influence significance of HROS? (c) if yes, then how does this measure modify the
association of treatment benefit in PFS with significant HROS? The following variables were used as
partitioning variables in the classification tree analysis: all three comparative PFS measures (HRPFS ,
∆MEDPFS and %∆MEDPFS), total sample size and total number of reported deaths. Bagging
method [89] was applied to identify the most important partitioning variable(s). All statistical
analyses were performed using R 3.0.2. A two-sided p value of < .05 was considered statistically
significant. ROC analysis was carried out using “ROCR” package [90]. Classification tree was
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Table 2: Summary of 74 comparisons (i.e. treatment to control comparisons) included in the meta-
analyses
Characteristics
Study phase – n(%)
Phase III 47 (63.5%)
Phase II/IIB 19 (25.7%)
Unknown 8 (10.8%)
Blinding status – n(%)
Open 38 (51.4%)
Blinded 15 (20.3%)
Unknown 21 (28.3%)
Sample size (n=74)
Median (Min, Max) 259 (41, 1349)
Number of deaths (n=60)
Median (Min, Max) 153 (19, 997)
Type of control – n(%)
Active 68 (91.9%)
Placebo 3 (4.1%)
Standard care 3 (4.1%)
Line of therapy – n(%)
First line 49 (66.2%)
2nd or beyond 25 (33.8%)
Increase in median PFS, ∆MEDPFS (n=72)
Median (Min, Max) 1.60 (-0.50, 10.90)
% increase in median PFS, %∆MEDPFS (n=72)
Median (Min, Max) 29.99 (-10.42, 294.60)
HR in PFS, HRPFS (n=68)
Median (Min, Max) 0.78 (0.24, 1.18)
HR in OS, HROS (n=63)
Median (Min, Max) 0.85 (0.37, 1.49)
constructed using “rpart” package [91] and for bagging method we have used “randomForest” package
[92].
Results
Description
We had a total of 74 treatment-to-control comparisons available from 65 publications for the meta-
analyses. The majority of these publications were published in the Journal of Clinical Oncology (28;
43%), Breast cancer research treatment (11; 17%) and Annals of Oncology (9; 14%), see Table 1. The
majority (44, 68%) of these studies recruited patients to treat as first line therapy. Forty-one (63%)
of these studies were phase III. In 60 studies comparison was made with active control, in 2 studies
comparison was made with placebo and in remaining 3 studies standard care was used as comparator.
5
Table 3: Number of cases (i.e. treatment to control comparisons) reporting significant (at 5% level)
difference in PFS and OS time
Overall survival (OS)
Progression free survival (PFS) HROS significant HROS not significant
HRPFS significant 12 21
HRPFS not significant 4 37
Level of significance is 5%.
The characteristics of the 74 comparisons are summarized in Table 2. Of the 74 comparisons, 73
(98.6%) were reported to be made in randomized set-up and 47 (63.5%) were based on phase III
trials. Only 15 (20.3%) comparisons were reportedly carried out in blinded fashion and blinding
status was not reported for 21 (28.3%) comparisons. The median total sample size was 259 and
the median number of deaths reported was 153. The majority (91.9%) of the comparisons included
active control in the study, and in 66.2% comparisons, treatment under investigation was the first line
therapy. The median HRPFS and HROS were 0.78 and 0.85, respectively. Further, on average, me-
dian PFS time was increased by 1.60 months which translates to 29.99% increase in median PFS time.
Of the 74 comparisons, significant (at 5% level) HRPFS and HROS were reported in 33 (44.6%) and
16 (21.6%) cases, respectively (see Table 3). The comparisons with significant HRPFS are 5.29 times
more likely to have significant HROS compared to the comparisons where HRPFS was not reported as
significant. However, more importantly, only 36.4% (12/33) of comparisons with significant HRPFS
also reported significant HROS .
Diagnostic accuracy (using ROC analysis)
ROC curves for each of HRPFS , ∆MEDPFS and %∆MEDPFS evaluating diagnostic accuracy to pre-
dict significant HROS are displayed in Figure 1. AUC from ROC curves based on diagnostic measure
of HRPFS (AUC=0.69) and ∆MEDPFS (AUC=0.70) were numerically close. However, %∆MEDPFS
offers relatively better diagnostic accuracy with AUC as 0.75. From the ROC curve of %∆MEDPFS
in Figure 1, the optimal cut-off point (according to Youden’s index) was 44.83%, for which the sen-
sitivity (i.e. true positive rate) was 81.3% and specificity (i.e. 1-false positive rate) 76.8%. It can be
interpreted as follows: if we set a predictive rule to classify the cases with improvement in median
PFS greater than 44.83% as producing significant HROS subsequently, then 81.3% of cases reporting
significant HROS will be correctly predicted and 76.8% of cases reporting non-significant HROS will
be correctly predicted. Another cut-off point of interest could be 33.33% for which the sensitivity
and specificity were 87.5% and 62.5%, respectively.
Diagnostic accuracy (using classification tree)
In classification tree approach, in addition to comparative PFS measures, number of deaths and sam-
ple size were also considered as predictor variables. Classification tree results based on 74 cases (i.e.
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Figure 1: ROC curves using treatment effect on PFS as diagnostic measure for prediction of sig-
nificant HROS at 5% level of significance. Treatment effect on PFS was assessed using (a) haz-
ard ratio (HRPFS), (b) increase in median PFS (∆MEDPFS) and (c) % increase in median PFS
(%∆MEDPFS). True positive rate was defined as proportion of correct prediction among the com-
parisons reporting significant HROS). False positive rate was defined as (% of wrong prediction
among the comparisons reporting non- significant HROS).
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Figure 2: Classification tree for predicting significant treatment effect on OS
l
l
l
l
l
l
l
l
l l
l
l
l
0 200 400 600 800 1000
0
50
10
0
20
0
30
0
Total number of deaths
%
in
cr
ea
se
 in
 m
ed
ia
n 
P
FS
l HROS  Significant
HROS  Not significant
Figure 3: Display of comparisons with statistical significance status of HROS in terms of % increase
in median PFS and total number of deaths
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comparisons) identified %∆MEDPFS and total number of deaths as diagnostic measures for signifi-
cant HROS . Importantly, we found %∆MEDPFS as a more important predictor variable compared
to HRPFS or ∆MEDPFS . This is very much consistent with our findings observed in the analysis
based on the ROC curve. The bagging method also suggested %∆MEDPFS as the most important
and total number of deaths as the second most important diagnostic measure for significant HROS .
Next, we performed classification tree analysis only on the 58 cases where information were available
for both %∆MEDPFS and total number of deaths. The classification tree results are displayed in
Figure 2. In 39 cases, increases in median PFS were shorter than 48.27%; and only 3 of these
cases showed significant HROS . There were 19 cases with increases in median PFS reported at
least 48.27%. Of these 19 cases, in 12 cases total deaths reported were less than 227 and 5 of
them reported significant HROS . In remaining 7 cases total deaths were 227 or more and 6 of them
reported significant HROS . In Figure 3, comparisons are displayed in terms of %∆MEDPFS and total
number of deaths. Figure 3 suggests that the treatment to control comparisons reporting statistically
significant HROS tend to have about 50% or higher median PFS increase and total number deaths
227 or more. The findings of Figure 2 and Figure 3 can be summarized as follows: There is only
small chance that study would produce significant HROS if increase in median PFS is less than
48.27%. Trials with median PFS increase of at least 48.27% seem to have better chance of producing
statistically significant HROS , and having a total of 227 or more OS events further improves the
likelihood of obtaining significant HROS .
Discussion
That a substantial improvement in PFS may be predictive of a corresponding difference in OS makes
common sense. However, what is often not obvious is the magnitude of PFS difference that is re-
quired to be reasonably confident of observing a statistically significant HROS . This is crucial in
late phase trials where therapeutic agents are being tested and the sponsor needs to decide whether
the observed PFS difference could be predictive of a significant and clinically meaningful difference
in OS and would merit a marketing authorization application (MAA). The ROC and classification
tree analyses employed here are very well suited for such a determination. For example, the ROC
approach gives us an overall assessment of diagnostic accuracy based on the AUC metric. On the
other hand, the classification tree approach is helpful in identifying non-linear association and influ-
ence of other factor, such as total number of deaths, in an interpretable and visible manner. Both
the approaches help us to choose an optimal operating point to guide the decision-making process.
Our study findings can be summarized as follows: First of all, ∆MEDPFS (i.e. percentage difference
in median PFS) is a relatively better diagnostic predictor compared to HRPFS . This is suggested
by both ROC analysis and classification tree analyses. Secondly, higher %∆MEDPFS tends to be
associated with significant HROS . However, our classification tree result suggests that higher num-
ber of deaths is also important in achieving significant HROS . The fact that the number of deaths
influences the result of statistical testing of HROS is very logical as deaths are considered as events
in OS analysis and increased number of events improves the chance of statistical significance [i.e.,
power] in survival analyses. Based on our study results, the surrogate threshold effect (STE) in terms
of %∆MEDPFS appears to be close to 50% increase in median PFS (ROC analysis: STE=44.83%;
Classification tree analysis: STE=48.27%). This suggests the studies with 50% improvement in me-
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dian PFS are more likely to produce significant HROS if the total number of OS events at the time
analysis is 227 or more. This result can be useful in the context of breast cancer trials in at least
two ways: first, a trial showing about 50% increase in median PFS may serve as a useful indicator of
statistically significant HROS while awaiting for OS data to mature. Secondly, if a prospective clinical
trial plans to show statistically significant HROS , then that trial should plan for approximately 227
OS events.
An alternate approach to assessing diagnostic accuracy is the use of Positive predictive value (PPV)
and Negative predictive value (NPV) curves introduced by Moskowitz and Pepe [93]. While Positive
predictive value (PPV) and negative predictive value (NPV) are great tools, these are not intrinsic
measures of diagnostic accuracy, being dependent on the prevalence. In our case, pre-valence refers
to prevalence of comparisons with statistically signficant HROS . In fact, Moskowitz and Pepe (2004),
when commenting on the applicability of their method in the discussion section of their paper note
”Study designs that result in a sample prevance that does not accurately reflect the true popula-
tion prevalence will produce biased estimates of PPV and NPV”. In their paper, they assume that
the data arose from a cohort type design where the sample estimates would be valid. Since we
are selecting a sample of studies from the whole population of studies using certain search criteria,
there is no reason to assume that the sample prevalence would match the true population preva-
lence in this case. Also, given the relatively small number of positive studies, we believe that there
is not enough data to draw a reliable PPV curve along the lines of Moskowitz and Pepe (2004).
While we do acknowledge the intuitive appeal of the PPV and NPV curves, we would like to empha-
size that the AUC would be a more appropriate metric for assessing diagnostic accuracy for our data.
There have been numerous studies examining the strength of surrogacy and the ability of a surrogate
measure such as PFS to predict OS. Most of the previous meta-analytic studies on metastatic breast
cancer attempted to measure the association between improvement in OS with improvement in PFS
and clinical benefit rate (CBR) [11, 7, 12, 13, 8, 14]. For example, Miksad et al. [12] found only
moderate correlation between HRPFS and HROS (R2 ranging between 0.35 to 0.59) in taxane and
anthracycline based therapies in breast cancer patients. Recently, Amiri-Kordestani et al. (2016)
[16] reported a moderate association between odds ratio (OR) of CBR and HRPFS (R2 = 0.52), but
failed to show any association with OR of CBR with HROS (R2 = 0.01) from 13 prospective studies
submitted to FDA. Our work takes a markedly different path. First, we are interested in assessing
the association of treatment effect on PFS with the ultimate interest being the observation or non-
observation of a significant HROS , whereas previous meta-analyses were mostly focused on exploring
the association between the treatment effects on PFS and OS. Secondly, we have also considered PFS
measures beyond HRPFS such as ∆MEDPFS (i.e. difference in median PFS) or %∆MEDPFS (i.e.,
percentage difference in median PFS). Thirdly, we have used fully data dependent non-parametric
approaches like empirical ROC curves and classification tree for the meta-analyses which, as far as we
know, have not been used before in applications of this type. Fourthly, we have also included other
factors such as total sample size and total number of deaths in evaluating the association between
PFS measures and significance of HROS . Last but not the least, we have included a comprehensive
list of all published studies since 2000 and hence the number of studies included in this current
investigation is relatively higher than previous published meta-analyses.
Our study has its limitations. Not all breast cancer studies published during the period under con-
sideration could be included, although the number is still quite high compared to previous meta
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analyses. The selection of studies was driven by common-sense, objective search criteria which were
rigorously applied. Thus, only 74 treatment to control comparisons from 65 prospective published
trials on breast cancer met the eligibility. The included trials were diverse in nature in terms of
patient population considered – some examples of patient population are patients with at least two
prior chemotherapies, anthracycline or taxane resistant patients, post-menopausal patients, HER2
positive patients, HER2 negative patients, just to name a few. Further, the included studies were
also diverse with regards to tumor type, tumor stage and drug under investigation. We have reported
only overall results from non-parametric analyses including all 74 studies; we did not have enough
studies to assess surrogacy in each of the categories formed by the combination of these different fac-
tors. Thus, the reported overall results may not be applicable in all set-up of breast cancer studies.
There is also potential for publication bias. To minimize the publication bias, we have considered
all the studies which were published and listed in PubMed database and met our search criteria.
Lastly, we have not looked into other cancer indications, although we cannot think of any reason
why the method would not be a useful tool in assessing surrogacy of PFS (or any other continuous
time-to-event endpoint, for that matter) in other indications and settings.
To conclude, empirical ROC curves and classification trees could be useful tools for assessing how
well treatment effect on PFS predicts weather HROS would be statistically significant or not in breast
cancer studies.
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